Session Details

F005 Skin Disease in Transplant Recipients and Immunosuppressed Patients

Fri, Mar 19, 9:00 AM - 11:00 AM
2 CME Available Forum

DESCRIPTION

Organ transplant recipients and other immunosuppressed patients have an increased risk of skin cancer development, progression, and death from skin cancer, as well as distinct presentations of inflammatory and infectious conditions. Dermatologists are uniquely positioned to care for these patients and optimize outcomes in the context of multidisciplinary care. This session will highlight key issues in the care of immunosuppressed patients, with a focus on prevention and management of multiple skin cancers, treatment of localized and advanced skin cancer, treatment of inflammatory and infectious skin disease, and recognition and mitigation of treatment fatigue.

LEARNING OBJECTIVES

1.

Summarize recommendations for screening, detection and management of multiple skin cancers in transplant and immunosuppressed patients, recognizing the role of multidisciplinary care.

2.

Prescribe topical and systemic therapy for treatment of precursor lesions and prevention of skin cancer in transplant and immunosuppressed patients.

3.

Diagnose inflammatory and infectious skin disease in transplant and immunosuppressed patients, and identify factors that contribute to treatment fatigue and discontinuation in this population.

DIRECTOR

Sean Christensen, MD, PhD, FAAD

Sean Christensen, MD, PhD, FAAD

Yale University School of Medicine

SPEAKERS

Lihi Atzmony, MD, IFAAD

Lihi Atzmony, MD, IFAAD

Samantha Guhan, MD, FAAD

Samantha Guhan, MD, FAAD

Nina Ran, MD, MS, FAAD

Nina Ran, MD, MS, FAAD

Emily S. Ruiz, MD, FAAD

Emily S. Ruiz, MD, FAAD

Annika P. Weinhammer, MD

Annika P. Weinhammer, MD

Nathalie C. Zeitouni, MD, FAAD

Nathalie C. Zeitouni, MD, FAAD

DISCLOSURES

Lihi Atzmony, MD, IFAAD

No financial relationships exist with ineligible companies.

Sean Christensen, MD, PhD, FAAD

inhibitor therapeutics – Advisory Board(Fees); Natera – Advisory Board(Honoraria); Regeneron Pharmaceuticals Inc – Advisory Board(Honoraria); Sol-Gel Technologies – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria);

Samantha Guhan, MD, FAAD

No financial relationships exist with ineligible companies.

Nina Ran, MD, MS, FAAD

Chronicle Medical Software – Consultant (1099 relationship)(Fees);

Emily S. Ruiz, MD, FAAD

Almirall – Consultant (1099 relationship)(Fees); Castle Biosciences, Inc – Investigator(Grants/Research Funding); Checkpoint Therapeutics – Consultant (1099 relationship)(Fees); Feldan Therapeutics – Consultant (1099 relationship)(Fees); Merck – Investigator(Grants/Research Funding); Regeneron – Advisory Board(Fees), Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Fees), Consultant (1099 relationship)(Fees);

Annika P. Weinhammer, MD

No financial relationships exist with ineligible companies.

Nathalie C. Zeitouni, MD, FAAD

Alpha Tau Medical – Investigator(Grants/Research Funding); Biofrontera AG – Consultant (1099 relationship)(Honoraria), Investigator(Grants/Research Funding); Castle Biosciences – Investigator(Grants/Research Funding), Speaker(Honoraria); Regeneron Pharmaceuticals, Inc. – Advisory Board(Honoraria), Investigator(Grants/Research Funding), Speaker(Honoraria); Replimune – Investigator(Grants/Research Funding); Sun Pharmaceutical Industries Ltd. – Advisory Board(Honoraria), Investigator(Grants/Research Funding);